BioLife Solutions officer plans March 2026 retirement

BioLife Solutions, Inc. reports that its Chief Quality and Operations Officer, Karen Foster, has decided to retire.

Rhea-AI Filing Summary

BioLife Solutions, Inc. reports that its Chief Quality and Operations Officer, Karen Foster, has decided to retire. She provided notice of her decision on January 8, 2026, and her retirement will be effective March 31, 2026. The company states that her decision to retire is not due to any disagreement with BioLife Solutions on operations, policies, or practices. The company also expresses appreciation for her service and extends best wishes for her retirement.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioLife Solutions (BLFS) disclose in this 8-K filing?

BioLife Solutions disclosed that its Chief Quality and Operations Officer, Karen Foster, has decided to retire effective March 31, 2026.

Who is retiring from BioLife Solutions (BLFS) and what is her role?

Karen Foster, the company’s Chief Quality and Operations Officer, has decided to retire from her position.

When will the retirement of BioLife Solutions executive Karen Foster take effect?

Karen Foster’s retirement from her role as Chief Quality and Operations Officer will be effective on March 31, 2026.

Did Karen Foster’s retirement involve any disagreement with BioLife Solutions (BLFS)?

No. The company states that Ms. Foster’s decision to retire was not the result of any disagreement regarding its operations, policies, or practices.

How did BioLife Solutions (BLFS) characterize Karen Foster’s contributions?

BioLife Solutions notes that it appreciates Ms. Foster’s services to the company and wishes her the best in retirement.

What is the event date referenced in the BioLife Solutions (BLFS) 8-K?

The report is based on an event dated January 8, 2026, when Ms. Foster provided notice of her decision to retire.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 05:03 PM Learn about SEC filing dates

false0000834365Nasdaq00008343652026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36362

94-3076866

(State or other jurisdiction of  incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

			o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Common Stock, par value $0.001 per share			BLFS			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 8, 2026, Karen Foster, the Chief Quality and Operations Officer of BioLife Solutions, Inc. (the “Company”), provided notice of her decision to retire from her position as Chief Quality and Operations Officer of the Company, effective March 31, 2026. Ms. Foster’s decision to retire from her position with the Company was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company appreciates Ms. Foster’s services to the Company and wishes her the best in retirement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BioLife Solutions, Inc.
Date: January 9, 2026			By:			/s/ Troy Wichterman
						Name: Troy Wichterman
						Title: Chief Financial Officer